Risk of bleeding events among non-valvular atrial fibrillation (NVAF) patients newly initiating on oral anticoagulants vs. warfarin using Japanese claims data.
Phase of Trial: Phase IV
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Haemorrhage
- Focus Therapeutic Use
- 29 Jun 2017 New trial record